Nivolumab+Ipilimumab+RT in MSS mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
- Status
- COMPLETED
- Phase
- PHASE4
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- Status
- WITHDRAWN
- Phase
- PHASE2
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
- Status
- COMPLETED
- Phase
- PHASE1
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Immunotherapy in Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
- Status
- TERMINATED
- Phase
- PHASE1
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3